Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1390

Shown on this page

Current sort

Live official records

Conditions: Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions: L606, Placebo; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 13
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Hypoxia, Skin Pigmentation
Interventions: Controlled desaturation (hypoxemia); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Posterior Fossa Ependymal Tumor
Interventions: Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Multiple System Atrophy
Interventions: Amlenetug, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Francisco, California + 18 more

Conditions: Gaucher Disease Type 1
Interventions: FLT201; Genetic
Lead sponsor: Spur Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more

Conditions: Chronic Pain
Interventions: QuantalX DELPHI-MD (TMS-EEG); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 25 more

Conditions: Type 1 Interferonopathies
Interventions: BI 3000202_low dose, BI 3000202_high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Interventions: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo matching BI 1291583; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 1,755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations
Interventions: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 21
States / cities: Fullerton, California • Los Angeles, California • Orange, California + 17 more

About this UCSF institution page

What this page lists: ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UCSF

Filter and sort this campus

Live official records

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Pulse Oximeter Accuracy in Healthy Humans During Hypoxia

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

A Gaucher Disease Gene Therapy Trial With FLT201

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

TMS-EEG Biomarkers for Chronic Pain

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

About this UCSF institution page